Merck KGaA CEO Sees Healthy Growth in All Key Parameters for 2019

The transcript discusses Merck's performance in 2018, highlighting growth in healthcare, life sciences, and performance materials. It covers expectations for the multiple sclerosis drug Mavenclad, regulatory challenges, and contributions from pharma pipeline licensing. The progress of acquiring Versum is detailed, emphasizing the benefits of a combined portfolio. The transcript concludes with growth opportunities in healthcare and life sciences, projecting a challenging year for performance materials but a positive long-term outlook.

What were the main areas of growth for Merck in 2018?

• Retail, finance, and education

• Tourism, hospitality, and entertainment

• Automotive, aerospace, and agriculture

• Healthcare, life sciences, and performance materials

What is Merck's expectation regarding the approval of Mavenclad in the US?

• They believe it will not be approved

• They have positive expectations based on approvals in other regions

• They have no expectations regarding its approval

• They are certain it will be approved

What role do pharmaceutical pipeline licensing activities play in Merck's business model?

• They are a regular part of the business model

• They are only considered for future planning

• They are not included in the business model

• They are a minor part of the business

What is Merck's strategic reason for acquiring Versum?

• To enter the automotive industry

• To diversify into the fashion industry

• To expand into the food industry

• To enhance their electronic materials portfolio

How did Merck respond to the stock market reaction following the Versum acquisition announcement?

• They commented extensively on the stock market reaction

• They received positive feedback from shareholders

• They ignored the feedback from shareholders

• They decided to withdraw the offer

Which sector does Merck see as having the most growth potential over the next 5 to 10 years?

• Automotive

• Healthcare

• Retail

• Tourism

What is Merck's outlook for their performance materials business in 2019?

• They expect it to be a strong year

• They plan to exit the business

• They anticipate a rough year

• They foresee no change